在饮食控制和运动基础上，接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的成人2型糖尿病(以下简称：T2DM)患者；On January 2, 2025, Eli Lilly and Co announced the official launch of Mufengda (Teriparatide Injection) in China, covering two indications.
According to Zhitong Finance APP, on January 2, 2025, Eli Lilly and Co announced that Mufengda (terzepatide injection) has officially been launched in China, covering two indications.
Two indications:
Adult patients with type 2 diabetes (referred to as T2DM) whose blood glucose is still poorly controlled despite treatment with metformin and/or sulfonylureas based on dietary control and exercise;
Long-term weight management for adults with an initial body mass index (BMI) meeting the following criteria based on controlled diet and increased exercise: ≥28 kg/m² (obesity), or ≥24 kg/m² (overweight) with at least one weight-related comorbidity (such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea, cardiovascular disease, etc.).
The above indications were approved by the National Medical Products Administration in May and July 2024, respectively.
The number of adult diabetes patients in China is approximately 0.148 billion. Currently, nearly half of diabetes patients in China do not achieve standard blood glucose control (HbA1c ≥7.0%). Mufengda can directly and indirectly act on various organs and tissues that lead to pathophysiological defects in T2DM, and can exert stronger efficacy in key pathogenic tissues such as pancreatic β cells.
The four specifications currently listed in China for Mufengda are: 2.5mg: 0.5ml, 5mg: 0.5ml, 7.5mg: 0.5ml, and 10mg: 0.5ml.